Prosecution Insights
Last updated: April 19, 2026

Impact Therapeutics (Shanghai), Inc.

6 pending office actions

Portfolio Summary

6
Total Pending OAs
1
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18552434 ORAL CAPSULE OF PARP INHIBITOR AND PREPARATION METHOD THEREOF BASQUILL, SEAN M 1614 Non-Final OA Sep 25, 2023
18549778 USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER ENGLISH, CONNOR KENNEDY 1625 Non-Final OA Sep 08, 2023
18259112 SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF ISMAIL, REHANA 1625 Non-Final OA Jun 23, 2023
18255476 SUBSTITUTED FUSED BICYCLIC COMPOUND AS KINASE INHIBITOR AND USE THEREOF SAMSELL, RILLA MARIE 1624 Non-Final OA Jun 01, 2023
18006603 COMBINATION THERAPY OF PARP INHIBITORS ROBINSON, MIKHAIL O'DONNEL 1627 Non-Final OA Jan 24, 2023
17769416 DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND NESTOR, DONNA MICHELLE 1627 Final Rejection Apr 15, 2022

Managing Impact Therapeutics (Shanghai), Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month